|
Sobi's interim report for the fourth quarter and full year 2011 will be published on 23 February 2012 at 8.30 a.m. CET. Conference call at 3.00 p.m. CET
Financial analysts and media are invited to a telephone conference at 3.00 p.m. CET the same day hosted by CEO Geoffrey McDonough and CFO Lars Sandström. The presentation will be held in English and can be followed live or afterwards on our web site www.sobi.com. Slides used in the presentation will be available on our web site prior to the telephone conference. Details for participation Please call:
SE: +46 (0)8 505 598 09
UK: +44 (0)207 750 99 50
US: +1 866 676 58 69 Yours sincerely,
Åsa Stenqvist,
VP Communications and Investor Relations (Acting)
Phone: +46 8 697 21 88 About Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 60 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2010 Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on OMX NASDAQ Stockholm. More information is available at www.sobi.com.
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
HUG#1587194
|
